Provided by Parkinson & Movement Disorder Alliance

This session, led by a movement disorder specialist, provides a comprehensive overview of the evaluation and management of essential tremor (ET). Participants will learn about clinical diagnostic criteria, the role of advanced imaging in distinguishing ET from other tremor disorders, and current evidence-based pharmacological and non-pharmacological treatment options. The session covers first- and second-line medications, novel non-invasive therapies such as transcutaneous afferent patterned stimulation (TAPS) and focused ultrasound, and the selection criteria for advanced interventions, including deep brain stimulation (DBS). Emerging therapies and future directions in ET management will also be discussed to equip healthcare providers with cutting-edge knowledge for improved patient care.

Estimated time to complete activity: 60 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1 AMA PRA Category 1.0 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Conduct a clinical diagnosis of essential tremor
• Understand the role of DaTscan in differentiating ET from PD tremor
• Know the first and second-line medications for ET
• Determine who might be a good candidate for deep brain stimulation
• Recommend new non-pharmacological treatment options for ET for their patients such as focused ultrasound thalamotomy and wearable devices

Faculty

Holly Shill MD, FAAN
Director, Lonnie and Muhammad Ali Movement Disorder Center
Bob and Renee Parsons Chair in Parkinson’s Disease and Movement Disorders
Professor, Department of Neurology, University of Arizona College of Medicine- Phoenix
Professor, Department of Neurology, Creighton University School of Medicine

Holly A. Shill, MD is the Director of Muhammad Ali Parkinson Center and Movement Disorder Program at Barrow Neurological Institute in Phoenix, AZ. She is a Professor in the Department of Neurology at both the University of Arizona College of Medicine- Phoenix as well as Creighton University School of Medicine. She holds the Bob and Renee Parsons Chair in Parkinson’s Disease and Movement Disorders at Barrow Neurological Institute.
Dr. Shill received her medical degree from the University of Arizona, College of Medicine. She completed her internship at St. Joseph’s Hospital and Medical Center in Internal Medicine. Dr. Shill completed her residency in neurology and a fellowship in movement disorders at Barrow Neurological Institute. She then served as a clinical fellow at the National Institutes of Health, studying movement disorders. She is board certified by the American Board of Psychiatry and Neurology. She has received numerous awards over the years including National Merit Scholar, induction into the Alpha Omega Alpha Medical Honors Society, and acceptance into the American Academy of Neurology’s Transforming Leaders Program.
She has many leadership roles at both the national and international level including being chair of the medical advisory board for the International Essential Tremor Foundation and committee engagement within the Parkinson Study Group Credentials Committee and the American Academy of Neurology Leadership University Subcommittee.
Dr. Shill’s research interests include risk factors for the development and progression of Parkinson’s disease, the pathogenesis of Essential Tremor and innovative treatments for both Parkinson’s and Essential Tremor.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Holly Shill MD, FAAN
• Grant or research support from: Intracellular Therapeutics, Supernus/US WorldMeds, Fasikl Inc.

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Cereval Therapeutics, Bukwang Pharmaceutical, UCB Pharma, and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Kyowa Kirin and AbbVie

• Britt Stone, MD
• Consultant or advisory board for Boston Scientific

• Jason Rivera, MPH
• No disclosures to report

• Clarisse Goas, NP
• Principal or site investigator for research supported by Prilenia Therapeutics

• Anissa Mitchel, LCSW
• No disclosures to report

• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Acadia, Amneal, and Supernus

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Acadia, Merz, AbbVie, Kyowa Kirin, and Ipsen.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org